- Latest Deal Type
- Financing Rounds
ProSkelia General Information
Provider of drug discovery and development intended to treat bone diseases. The company's portfolio of technology includes an exclusive program named oestradiol glucoside ("E2G"), which completed a Phase IIa clinical study for the treatment of menopausal symptoms, along with drugs related to the preclinical development and in vivo pharmacology.
Discovery Tools (Healthcare)
- 102 route de Noisy
- 93230 Romainville
Want detailed data on 3M+ companies?
What you see here scratches the surfaceRequest a free trial
Want to dig into this profile?
We’ll help you find what you needLearn more
ProSkelia Valuation & Funding
1Total Documents Applications and Grants
000Total Patents Families
000Expiring in next 12 mo
ProSkelia Recent Patent Activity
|Publication ID||Patent Title||Status||First Filing Date||Technology (CPC)||Citations|
|US-20040265808-A1||Diagnosing osteoporosis by analyzing the gene expression of given nucleotide sequence in sample; detecting amplified cdna||Inactive||05-Apr-2001||000000000|
ProSkelia Former Investors
|Investor Name||Investor Type||Holding||Investor Since||Participating Rounds||Contact Info|